Go Pro
NYSE:SQZ

SQZ Biotechnologies (SQZ) Stock Price, News & Analysis

SQZ Biotechnologies logo
$0.02 0.00 (0.00%)
As of 07/31/2026

About SQZ Biotechnologies Stock (NYSE:SQZ)

Advanced

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.02
52-Week Range
$0.25
$3.56
Volume
N/A
Average Volume
455,220 shs
Market Capitalization
$707.78 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

SQZ Biotechnologies (NYSE: SQZ) is a clinical‐stage biotechnology company that specializes in the development of novel cell therapies for oncology and infectious diseases. The company’s proprietary Cell Squeeze® platform uses a microfluidic device to temporarily open pores in cell membranes, enabling the delivery of proteins, peptides, mRNA and other cargo directly into the cytosol without relying on viral or chemical vectors. This approach aims to generate potent antigen‐presenting cells and engineered T cells while reducing manufacturing complexity and safety concerns common to viral‐based methods.

The company’s pipeline includes both oncology and infectious disease programs. Key programs include an HPV‐targeted antigen‐presenting cell therapy designed to stimulate a robust immune response against HPV16‐associated malignancies and a series of CAR‐T candidates engineered via the Cell Squeeze platform for solid tumors. SQZ Biotechnologies has collaborations with academic institutions and biopharmaceutical partners to advance preclinical and clinical studies, with the goal of demonstrating proof‐of‐concept in a range of indications.

Founded in 2014 and headquartered in Cambridge, Massachusetts, SQZ Biotechnologies completed its transition to a publicly traded company in 2021 through a merger with a special purpose acquisition company. The company operates a dedicated manufacturing facility in the Greater Boston area and continues to expand research partnerships to validate its platform across multiple cell therapy modalities. As SQZ advances its lead candidates through regulatory filings and clinical trials, it aims to redefine the delivery and engineering of cell‐based medicines for patients worldwide.

AI Generated. May Contain Errors.

Receive SQZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SQZ Stock News Headlines

Arsenal Yards attracts another life sciences tenant
SQZB SQZ Biotechnologies Company - Seeking Alpha
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
SQZ Biotechnologies Co Ordinary Shares
SQZ Biotechnologies Company (SQZB)
Sqz Bio (SQZB) Earnings Dates & Reports
See More Headlines

SQZ Stock Analysis - Frequently Asked Questions

SQZ Biotechnologies' stock was trading at $0.0240 on January 1st, 2026. Since then, SQZ stock has increased by 0.0% and is now trading at $0.0240.

SQZ Biotechnologies (NYSE:SQZ) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($8.00) EPS for the quarter, missing analysts' consensus estimates of ($5.60) by $2.40. The firm earned $4.76 million during the quarter, compared to analyst estimates of $11.64 million. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 119.83% and a negative net margin of 369.96%.

SQZ Biotechnologies shares reverse split on the morning of Friday, July 7th 2023.The 1-10 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

SQZ Biotechnologies (SQZ) raised $75 million in an initial public offering on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include Minerva Neurosciences (NERV), Illumina (ILMN), NVIDIA (NVDA), Oramed Pharmaceuticals (ORMP), Absci (ABSI), Allogene Therapeutics (ALLO) and Beam Therapeutics (BEAM).

Company Calendar

Last Earnings
11/10/2021
Today
8/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSE:SQZ
CIK
1604477
Fax
N/A
Employees
1,620
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
($2.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.46 million
Net Margins
-369.96%
Pretax Margin
-408.99%
Return on Equity
-119.83%
Return on Assets
-59.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.50
Quick Ratio
3.50

Sales & Book Value

Annual Sales
$18.16 million
Price / Sales
0.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.94 per share
Price / Book
0.01

Miscellaneous

Outstanding Shares
29,491,000
Free Float
24,772,000
Market Cap
$707.78 thousand
Optionable
Not Optionable
Beta
2.34

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:SQZ) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners